MedTrace Logo

Hepatitis c and Vitamin D and Iron Status

NCT03166280 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 87

Last updated 2017-05-25

No results posted yet for this study

Summary

HCV is associated with vitamin D deficiency. Iron overload is frequently occurred in chronic hepatitis C patients; more than one third of HCV positive patients have elevated serum iron, ferritin, and transferrin which were linked to bad prognosis. Hepcidin is a regulatory peptide that is mainly synthesized by the liver cells and plays an important role in iron homeostasis. There is an interaction between iron metabolism and vitamin D metabolism. Iron is essential for vitamin D activation and vitamin D deficiency is associated with elevated hepcidin level, which partly accounts for anemia associated with vitamin D deficiency. Up to our knowledge, little is known about the association between vitamin D status and iron metabolism in HCV patients.

Conditions

  • Hepatitis C

Interventions

DRUG

Sofosbuvir 400 mg

treatment for hepatitis c by sofosbuvir (Sovaldi) 400 mg/day

DRUG

Daclatasvir 60 mg/day

treatment for hepatitis c by Daclatasvir 60 mg/day

Sponsors & Collaborators

  • Eman Sayed Hassan Abd Allah

    lead OTHER

Principal Investigators

  • Eman SH Abd Allah, PHD · Assiut University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-30
Primary Completion
2017-11-30
Completion
2018-05-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03166280 on ClinicalTrials.gov